Top Page
Impedimed Limited
(Sydney:IPD)
Impedimed Limited (IPD) vs. S&P 500 (SPY)
Impedimed Limited Business Overview & Revenue Model
Impedimed Limited Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 10.32M | 11.34M | 10.57M | 8.41M | 5.74M | Gross Profit |
| 9.01M | -13.65M | -13.35M | -12.20M | -12.89M | EBIT |
| -19.04M | -22.85M | -21.23M | -23.02M | -25.51M | EBITDA |
| -22.05M | -20.49M | -18.65M | -20.70M | -24.07M | Net Income Common Stockholders |
| -19.79M | -20.52M | -19.87M | -20.71M | -21.38M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 24.63M | 45.71M | 40.73M | 19.68M | 19.66M | Total Assets |
| 46.99M | 68.74M | 58.70M | 34.20M | 33.06M | Total Debt |
| 1.14M | 1.45M | 170.00K | 474.00K | 871.00K | Net Debt |
| -23.49M | -44.26M | -40.56M | -19.21M | -18.79M | Total Liabilities |
| 6.24M | 7.86M | 7.66M | 8.69M | 5.70M | Stockholders Equity |
| 40.74M | 60.88M | 51.04M | 25.51M | 27.36M |
| Cash Flow | Free Cash Flow | |||
| -20.89M | -24.09M | -20.89M | -15.71M | -21.38M | Operating Cash Flow |
| -17.79M | -18.05M | -15.66M | -13.26M | -19.22M | Investing Cash Flow |
| -3.10M | -6.04M | -5.22M | -2.46M | -2.16M | Financing Cash Flow |
| -481.00K | 27.93M | 39.92M | 16.47M | 30.16M |
Impedimed Limited Technical Analysis
Impedimed Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $3.14B | 8.88 | 26.42% | 3.19% | 54.37% | 310.22% | |
76 Outperform | $1.48B | 89.38 | 9.23% | ― | 10.79% | 5.20% | |
68 Neutral | $18.02B | 48.69 | 20.61% | 1.57% | 6.35% | 5.97% | |
64 Neutral | $124.16B | 29.80 | 15.38% | 1.78% | 8.00% | 9.09% | |
64 Neutral | AU$16.55M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
52 Neutral | $5.35B | 3.96 | -42.60% | 2.86% | 17.58% | 1.27% | |
51 Neutral | $79.07M | ― | -51.08% | ― | 10.22% | -2.94% |
Impedimed Limited Earnings Call Summary
Impedimed Limited Corporate Events
ImpediMed Limited reported a record revenue of A$3.4 million for the third quarter of FY25, alongside a significant increase in annual recurring revenue and total contracted value. The company appointed Scott Long as the new SVP of Sales, aiming to enhance sales operations and market penetration. Despite a decrease in total SOZO unit sales, the company saw a 10% increase in US sales and maintained low churn rates. ImpediMed is focusing on converting leads into sales, supported by increased media activity and conference participation. The company ended the quarter with a cash balance of A$27.9 million, bolstered by a growth capital facility drawdown.
ImpediMed Limited has announced a change in the director’s interest notice, specifically for Ms. Christine Emmanuel-Donnelly. The change involves the issuance of shares in lieu of 30% of director fees for the quarter ended 31 March 2025. This adjustment reflects a strategic decision to align director compensation with company performance, potentially impacting the company’s financial management and shareholder relations.
Impedimed Limited announced a change in the director’s interest, with Fiona Bones acquiring an additional 197,647 ordinary shares, bringing her total to 1,506,230 shares. This acquisition was made through the issue of shares in lieu of 30% of director fees for the quarter ended March 31, 2025, reflecting a strategic approach to compensation and potentially strengthening the director’s alignment with shareholder interests.
ImpediMed Limited has announced a change in the director’s interest, with Mr. Andrew Grant acquiring an additional 197,647 ordinary shares, bringing his total to 2,506,230 shares. This acquisition was made through the issuance of shares in lieu of 30% of his director fees for the quarter ended March 31, 2025, reflecting a strategic move to align director compensation with company performance, potentially impacting stakeholder perceptions positively.
Impedimed Limited announced a change in the director’s interest, with Ms. Janelle Delaney acquiring additional ordinary shares. The acquisition was part of a compensation arrangement where shares were issued in lieu of 30% of her director fees for the quarter ended March 31, 2025. This move reflects the company’s strategy to align director compensation with shareholder interests, potentially impacting the company’s governance and financial strategies.
Impedimed Limited has announced the issuance of 815,481 fully paid ordinary shares to its executives as part of their remuneration for the quarter ended March 31, 2025. This move is part of the company’s Executive Share Plan and reflects its strategy to align executive compensation with company performance, potentially impacting its financial structure and stakeholder interests.
Impedimed Limited announced the issuance of 942,353 ordinary fully paid shares to its non-executive directors as part of the Non-Executive Director Share Plan, covering 30% of director fees for the quarter ending March 31, 2025. This move is part of the company’s strategy to align the interests of its directors with shareholders, potentially impacting the company’s governance and financial structure.
ImpediMed Limited announced that it will release its quarterly cash flow report for the period ending March 31, 2025, on April 30, 2025. The company will host an investor conference call on the same day, led by CEO Dr. Parmjot Bains and CF&OO McGregor Grant, providing stakeholders an opportunity to engage with management and discuss the company’s financial performance and outlook.
ImpediMed Limited has announced a change in the address of its Sydney share registry office, which is now located at Liberty Place, Level 41, 161 Castlereagh Street, Sydney NSW 2000. This move is part of the company’s ongoing operational adjustments, although the telephone numbers and postal address remain unchanged. This update is approved by the Company Secretary and reflects ImpediMed’s commitment to maintaining efficient operations and communication with stakeholders.
ImpediMed Limited has announced that the recent U.S. tariffs on imports are not expected to have a significant impact on its business or supply chain in the short to medium term. The company’s SOZO device is manufactured in the U.S. with many components sourced locally, and it maintains a sufficient inventory to mitigate potential supply chain disruptions. ImpediMed will continue to monitor the situation and update stakeholders if necessary.
Impedimed Limited announced the cessation of certain securities, including 4,362,750 options that expired without exercise and 201,962 performance rights that lapsed due to unmet conditions as of March 31, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial management and strategic direction.
ImpediMed Limited has released its interim financial report for the half-year ending December 31, 2024, showing a 26% increase in revenue from ordinary activities, amounting to $6.008 million. Despite the revenue growth, the company reported a net loss of $11.146 million, which marks a 15% decrease in losses compared to the previous period. The report indicates no dividends were declared or paid during this period, and the net tangible assets per ordinary security decreased from $0.03 to $0.02. This financial performance reflects the company’s ongoing efforts to improve its market position while managing operational challenges.
Impedimed Limited announced a proposed issue of securities, with a maximum of 12,491,870 warrants set to be issued. This strategic move aims to bolster the company’s financial position, potentially enhancing its operational capabilities and market competitiveness within the medical technology industry.
ImpediMed Limited has secured a US$15 million growth capital facility from SWK Funding LLC to support its strategic growth and commercialization activities. This financing provides ImpediMed with the financial flexibility needed to execute its business plan and capitalize on market opportunities, positioning the company for long-term success and value creation for shareholders.